Index of contractile asymmetry improves patient selection for CRT: a proof-of-concept study

Nearly one-third of heart failure (HF) patients do not respond to cardiac resynchronization therapy (CRT) despite having left bundle branch block (LBBB). The aim of the study was to investigate a novel method ...
Source: Cardiovascular Ultrasound - Category: Radiology Authors: Tags: Research Source Type: research

Related Links:

Yolanda Benito1, Pablo Martinez-Legazpi1*, Lorenzo Rossini2, Candelas Pérez del Villar1, Raquel Yotti1, Yolanda Martín Peinador3, Daniel Rodríguez-Pérez4, M. Mar Desco4, Constancio Medrano1, Jose Carlos Antoranz4, Francisco Fernández-Avilés1, Juan C. del Álamo2,5 and Javier Bermejo1 1Department of Cardiology, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón and CIBERCV, Madrid, Spain 2Department of Mechanical and Aerospace ...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Conclusion: This study observed an inverse correlation between plasma LDL cholesterol and heart function in individuals with T2DM. Patients with higher levels of plasma LDL cholesterol had worse left ventricular function. Therefore, plasma LDL cholesterol may be a modifiable risk factor of heart failure in diabetes, but prospective studies are necessary to confirm this finding. Introduction Type 2 diabetes mellitus (T2DM) is a metabolic disease that affects a considerable number of patients worldwide (1). Among diabetic individuals, cardiovascular disease (CVD) is the leading cause of morbidity and mortality (2). C...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Some patients with congestive heart failure have greater improvement of cardiac remodelling after cardiac resynchronisation therapy (CRT) and they are identified as super-responders (SRs). It remains unclear i...
Source: Cardiovascular Ultrasound - Category: Radiology Authors: Tags: Research Source Type: research
Mitral E/E’ for assessment of left ventricular diastolic function Mitral E/E’ for assessment of left ventricular diastolic function E/E’ measured using a combination of mitral flow Doppler and tissue Doppler of mitral annulus is an important measure of left ventricular diastolic function. Assessment of diastolic function of the left ventricle is assuming more importance after the recognition of diastolic heart failure which is otherwise known as heart failure with preserved ejection fraction (HFpEF). As the population ages, frequency of HFpEF is on the rise. The image illustrates measurement of E’ b...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Uncategorized mitral flow Doppler tissue Doppler of mitral annulus Source Type: blogs
This is a middle-aged male with h/o with a history ofheart failure with severely reducedejection fraction due to dilated ischemic cardiomyopathy (EF 5-10%), probably with some component of non-ischemic cardiomyopathy, with h/o CABG, who is status post ICD placement (and previous appropriate shocks for VT) and biventricular pacer ( " cardiac resynchronization therapy " ), who is on amiodarone for VT suppression, and has h/o LV thrombus and is on chronicanticoagulation with warfarin.He presented forparoxysmal nocturnal dyspnea that didn't resolve with use of his home prn diuretics.  He...
Source: Dr. Smith's ECG Blog - Category: Cardiology Authors: Source Type: blogs
EBR Systems said yesterday that it launched a 350-patient investigational device exemption trial of its Wise wireless pacemaker it hopes to use to win FDA approval. Sunnyvale, Calif.-based EBR’s device uses a subcutaneous generator to wirelessly deliver ultrasound energy to a “pellet” implanted in the right ventricle, which it uses to synchronize the left and right ventricles. The system is designed to eliminate the need for a left ventricular lead by allowing the operating physician to place the stimulation “pellet” in a patient-specific location inside the left ventricle. The FDA approv...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials Cardiac Rhythm Management EBR Systems Inc. Source Type: news
EBR Systems said yesterday that it raised $50 million to back a clinical trial for the wireless cardiac pacemaker it’s developing after winning CE Mark approval for a second-generation wireless transmitter. EBR’s device, which it calls wireless stimulation endocardially or Wise, uses a subcutaneous generator to wirelessly deliver ultrasound energy to a “pellet” implanted in the right ventricle, which it uses to synchronize the left and right ventricles. The system is designed to eliminate the need for a left ventricular lead by allowing the operating physician to place the stimulation “pe...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Funding Roundup Regulatory/Compliance Wall Street Beat Cardiac Rhythm Management EBR Systems Inc. Source Type: news
Although mechanical dyssynchrony parameters derived by speckle tracking echocardiography (STE) may predict response to cardiac resynchronization therapy (CRT), comparability of parameters derived with differen...
Source: Cardiovascular Ultrasound - Category: Radiology Authors: Tags: Research Source Type: research
Cardiac resynchronization therapy (CRT) is an established therapy for symptomatic heart failure (HF). Unfortunately, many recipients remain nonresponders. Studies have revealed the potential role of multipoint pacing (MPP) in improving response and outcomes. The aim of this study is to compare the effects of MPP against those of standard biventricular pacing (BVP) on (i) ventriculoarterial coupling (VAC) and energy efficiency of the failing heart, (ii) diastolic function, (iii) quality of life, and (iv) NT‐proBNP levels and glomerular filtration rate (GFR) during a follow‐up of 13 months. HUMVEE is a single‐cent...
Source: Annals of Noninvasive Electrocardiology - Category: Cardiology Authors: Tags: ORIGINAL ARTICLE Source Type: research
IntroductionPulmonary transit time (PTT) assessed with contrast‐enhanced ultrasound (CEUS) is a novel tool to evaluate cardiac function. PTT represents the time for a bolus of contrast to pass from the right to the left ventricle, measured according to the indicator dilution principles using CEUS. We investigated the hypothesis that PTT is a measure of general cardiac performance in patient populations eligible for cardiac resynchronization therapy (CRT). MethodsThe study population consisted of heart failure patients referred for CRT with NYHA class II–IV, left ventricular ejection fraction (LVEF)≤35% and QRS&g...
Source: Echocardiography - Category: Cardiology Authors: Tags: ORIGINAL INVESTIGATION Source Type: research
More News: Cardiac Resynchronization Therapy | Cardiology | Cardiovascular | Heart | Heart Failure | Radiology | Study | Ultrasound